Index

abbreviations
micrograms and nanograms, 192–193
of drug names, 195–196
of ‘unit’ to ‘u’, 193
prescribing errors due to, 191–192
absolute risk, 125
absolute risk reduction (ARR), 125–126
absorption of a drug, 66–67
bioavailability, 66
blood flow, 68
drug interactions, 80
first pass metabolism, 68
gastric motility and emptying, 67–68
lipid solubility, 67
surface area for, 67
time factors, 68
acne vulgaris,
treatment complications, 183
adherence to medication.
see concordance
ADME, see pharmacodynamics
administration of drugs
potential errors in, 9–10
rate per unit time calculations, 160–162
routes of, 65–66
adverse drug reactions
(ADRs), 82–83. see also drug interactions
patients at risk of, 82–83
reporting, 83
Type A reactions, 82
Type B reactions, 82
advertising of drugs, 57, 62–63
affinity of a drug, 76–77
agonists, 76–77
amount of a drug, unit for, 152
answers to practice questions, 171–178
agonists, 77–78
antimicrobials
controlling resistance to; infection control, 137–138
prudent prescribing, 135–137
surveillance, 133–135
policies on prescribing, 131
resistance to, 131–132
consequences of, 132–133
societal impact of overuse, 130–131
widening access to, 131
applied pharmacology, 75–79
pharmacokinetics, 65–75
pharmacodynamic, 75–79
pharmacokinetics, 65–75
approved drug names, 191–196
autonomy, respect for, 46–47
bacteria resistant to antimicrobials, 132
benefits about health, 19–20,
53, 60–61, 110–111
beneficence, 110
benefits vs. harms of a treatment, 125–127
best interests of patient, 38
bioavailability of a drug, 66, 167–168
blood flow
and drug absorption, 68
and drug distribution, 68–69
Bolam v Friern Hospital Management Committee (1957), 3
Bolitho v City and Hackney HA (1997), 33, 35
brand names of drugs, 195–196
breakthrough analgesia
doses, calculating, 170
Byrne & Long, consultation model, 16
calculation skills,
answers to practice questions, 171–178
concentrations, 153–156
dose calculations, 156–160
palliative care, 169–171
rate of drug administration per unit time, 160–162
simple pharmacokinetic calculations, 164–169
unit costs of drugs, 162–163
units of measurement, 147–153
Calgary–Cambridge model, 18
Cardozo judgement,
informed consent, 36
carrier mechanisms, drugs acting on, 78–79
case control studies, 123
case reports/series, 123
cases of law, 40
Chester v Afshar (2004), 37–38
childhood vaccination programme, 140–141
civil versus criminal law, 31
clinical effectiveness of a drug, 120–121
clinical governance, 8–10
Clinical Management Plans (CMPs), 3, 11, 31,
34, 183
clinical negligence, 33
case law example, 33
codes of conduct, 49–50
cohort studies, 123
common law, 32
communicable diseases, 138
communication skills, 18–19
and concordance, 111,115
and information sharing, 11
competencies
communicating with patients, 116
competency levels, 8
concordance, 112–114
frameworks for prescribing, 180
compliance. see concordance
costs of drugs, 120
cost calculating, 162–163
cost-effectiveness, 121–122
cross sectional surveys, 123
Crown report (1989), 2
Crown report (1999), 1–2
cultural differences in health
beliefs, 61–62
Cumberlege report, 1
cytochrome P450
iso-enzymes, 73
decimal point errors, 193
decision making
computer support, 26
during diagnosis, 21–22
influences on prescribing, 24
models of, 23
prescribing errors, 187
principles of good
prescribing, 24–25
deontological ethics, 43–44
dermatological conditions, 180
acne vulgaris, 183
prescribing for, 181–182
skin care, 181
topical and systemic
medications, 182–183
diabetes, 102–103
insulin therapy, 104–105
monitoring of, 105
non-insulin treatment, 196–98
diagnosis, 21–22
distribution of a drug, 68
barriers to, 70–71
drug interactions, 79–82
protein binding, 69–70
volume of, 71–72
doctors
non-medical reasons for
prescribing, 54–56
other influences on, 56–58
patient pressure on, 59–60
sanctioning the sick
role, 54
dose calculations, 156, 158, 159
based on body surface area, 158–159
based on body weight, 156–158
practice exercises, 159–160
dose units, reducing errors in, 192–194
dosing schedules, errors due
to unusual, 193–195
drug administration per
unit time
drops per minute, 160
milligram per kg, 161–162
millilitres per hour, 160–161
practice calculations, 162
drug interactions, 79. see
also adverse drug
interactions (ADRs)
drugs involved in, 80
patients at risk of, 79–80
pharmacodynamic
interactions, 81–82
pharmacokinetic
interactions, 80–81
drug names, errors arising
from, 189
duty of care, 32–34
EASE mnemonic, 25
educational preparation for
extended prescribers, 4–5
efficacy of a drug, 76–77, 120–121
electronic prescribing
systems, 194
enterohepatic cycling, 74
enzymes
drugs acting on, 78
effect of CYP450
iso-enzymes on drug
excretion, 73
errors. see prescribing errors
ethic issues, 42–43
codes of conduct, 49–50
deoentological ethics, 43–44
paternalism, 43
pharmaceutical companies,
50–51
principles-based approach,
46–49
research ethics, 51–52
subjective ethics, 42–43
utilitarian ethics, 44–45
evidence-based prescribing,
119
benefits versus harms of a
treatment, 125–127
Index

checking the evidence, 122–123
cost–effectiveness, 121–123
facts and figures, 119–120
finding the evidence, 127
improvements 120
medicalisation, 54

health care professional, 83
health economic modelling, 120–121
healthcare associated infections (HCAIs), 134–135
healthcare professionals (HCPs)
changing roles and relationships, 7–8
consultations with, 23

heparin, dosage errors, 193
Hippocratic Oath, 49
hospitality from pharmaceutical companies, 51

immunisation. see vaccination
independent prescribers (IPs), legal definition, 31
individualising drug therapy, 83
infectious diseases
control of, government strategy, 137–138
immunisation against, 138–141
notifiable by law, 138
information sharing, 10–11
informed consent. see consent
insulin
dosage errors, 193
therapies, 83

internet information, dangers of, 62–63
ion channels, drugs acting at, 78
judge made law, 32
justice, 47–48
Kant, Immanuel, 44

laissez-faire practice, 43

lifelong learning, 35
ligands, 76
ligand–receptor complex, 76
lipid solubility of a drug, 67
Local Research Ethics Committee (LREC), 117–18
locus of control, 50
mass, units of, 149–151
maximum drug response (Emax), 76
McLennan v Newcastle HA (1992), 37
measurement units, 147–148
practice calculations, 152–153
prefixes, 148
units of amount, 152
units of mass, 149–151
units of volume, 148–149
media influence, 62–63
medicalisation, 54

Medicinal Products: Prescriptions by Nurses etc Act (1992), 30
Medicines Act (1968), 30, 39
Medicines and Human Use (Prescribing) (Miscellaneous Amendments) Order (2006), 31

Mental Capacity Act (2005), 38
meta-analysis technique, 123
metabolism of a drug, 72
cytochrome P450 isoenzymes, 73
drug interactions, 81
first pass metabolism, 68
metformin, diabetes treatment, 103
Misuse of Drugs Act, 39
mixing of drugs in same syringe, 38–39
moles (units of amount), 152
morphine, 193
changing from oral dose to injection, 170–171
for breakthrough pain, 170
multidisciplinary team context, 7, 13–14
clinical governance, 8–10
communication and information sharing, 10–11
teamwork, 7–8, 11–13
names of drugs, errors arising from, 189
National Patient Safety Agency (NPSA), 10, 29, 147, 189
negligence, 29, 32, 33–34
Neighbour, Roger, consultation model, 17
NHS impact on prescribers, 58
non-compliance, 108–109
nonmaleficence, 47
non-medical prescribing legislation, 1–3
reasons for, 54–56
supplementary prescribing, 3–4
training for, 4–5
notifiable diseases, 138
number needed to treat (NNT), 126
nurses
consultations with, 20–21
introduction of IP legislation, 1–2
patient relationship and concordance, 114, 115–117
role in diagnosis, 21–22
odds ratios, 126–127
overseas travel, health risks, 141
palliative care
breakthrough analgesia doses, 170
mixing of drugs issue, 39
oral morphine to diamorphine injection, 170–171
practice calculations, 171
syringe drivers, 169–170
paternalism, 43
Patient Group Directions (PGDs), 30
patients. see also concordance
at risk of ADRs, 82–83
at risk of drug interactions, 79–80
autonomy and choice, 46–47
empathising with, 55–56
expectations of, 60, 136–137
health beliefs of, 19–20, 53, 60–61, 110–111
media influences on, 62–63
pressurising doctors, 59–60
reasons for wanting a prescription, 59–60
Pendleton et al., consultation model, 16–17
pharmaceutical industry
code of practice, 50–51
influencing prescribers, 57–58
research ethics, 51–52
Pharmacist Only Medications (P), 2, 30
pharmacists
code of ethics for, 49–50
consultations with, 22–23
dispensing errors, 34, 190–191
errors made by, 9
independent prescribing for, 3
training in supplementary prescribing, 3–4
pharmacodynamics, 75–76
drug dose, 76–78
drug interactions, 81–82
pharmacokinetic calculations, 164
bioavailability, 167–168
half-life, 164–167
practice calculations, 168–169
pharmacokinetics, 65
absorption, 66–68
distribution, 68–72
drug interactions, 80–81
excretion, 73–75
metabolism, 72–73
routes of drug administration, 65–66
pharmacology. see applied pharmacology
philosophical ethics, 43–45
placebos, 59
plasma protein, drug binding, 69
potency of a drug, 77
prandial regulators, diabetes, 103
prefixes, UK metric system, 148
Prendergast v Sam Dee (1989), 34–35
prescribing
antimicrobials, 135–137
factors influencing, 24
legislation relevant to, 1–3, 29–31
NHS support for, 58
non-medical reasons for, 54–56
patience pressure, 59–60
principles of good, 24–25
repeat prescriptions, 25
prescribing errors, 187
abbreviations, 195–196
drugs acting at enzyme systems, 78
drugs acting at ion channels, 78
drugs acting at receptors, 76
drugs acting on carrier mechanisms, 78–79
prescribers
antimicrobials, 135–137
factors influencing, 24
Legislation relevant to, 1–3, 29–31
NHS support for, 58
non-medical reasons for, 54–56
patient pressure, 59–60
principles of good, 24–25
repeat prescriptions, 25
prescribing errors, 187
abbreviations, 195–196
controlled drugs (CDs), 196
decision making, 188
definition of, 187
dose units, 192–193
prescription writing errors, 188–189
prescription writing standards, 190–191
unusual dose frequencies, 193–195
prescription charges, 24
Prescription Only Medicines (POMs), 2, 29–30
principles-based approach, 46
beneficence, 47
confidentiality, 48
fidelity, 48–49
justice, 47–48
nonmaleficence, 47
privacy, 48
respect for autonomy, 46–47
veracity, 48
promotion of drugs by pharmaceutical companies, 57–58
protein binding, 69–70
psoriasis, treatment of, 182–183
psychology and sociology, 53, 63
health beliefs, 60–61
non-medical reasons for prescribing, 54–56
other influences on doctors, 56–58
patient pressure, 59–60
patients and the media, 62–63
patients’ reasons for wanting a prescription, 60
placebos, 59
race and culture, 61–62
sociological models, 53–54
Public Health (Control of Disease Act) (1984), 138
Public Health (Infectious Diseases) Regulations (1988), 138
public health perspective, 130
antimicrobials, 131;
resistance to, 131–132;
consequences of, 132–133;
controlling, 133–139;
societal impact of prescribing, 130–131
health of travellers overseas, 141
vaccination issues, 139–141
racial differences in health beliefs, 61–62
randomised controlled trials, 123
receptors, drugs acting at, 76
record keeping
NMC guidelines, 25
sharing of information, 10–11
relative risk, 125
relative risk reduction (RRR), 126
renal excretion of a drug, 74
repeat prescriptions, 25
reporting
of adverse drug reactions, 36, 83
of drug errors, 10
research ethics, 51–52
resistance to antimicrobial agents, 131–132
consequences of, 132–133
controlling, 133;
prudent prescribing, 135–137;
surveillance, 133–135
responsibilities of prescribers, 34–35
risks, absolute versus relative, 125–126
Scholendorff v Society of New York Hospital (1914), 36
sharing of information, 10–11
sick role, 53–54
sociological models, 53–54
sore throat studies
empathising with patient, 55–56
health beliefs of patients, 61
societal impact of prescribing, 130–131
standard of conduct, 49–50
statute law, 32
statutes, 40
steady state plasma concentration, 164–166
Stott & Davies, consultation model, 16
subjective ethics, 42–43
sulphonylureas, diabetes treatment, 103
supplementary prescribing, 3–4
legal definition, 31
teamwork, 11–12
surveillance of antimicrobial prescribing, 133–135
syringe drivers, 169–170
mixing of drugs issue, 38–39
systematic reviews, 122–123
systemic antibiotics, acne treatment, 185
teamwork, 7–8
between IPs and SPs, 11–12, 34
therapeutic index, 69, 73
thiazolidinediones, diabetes treatment, 103–104
topical medications, 152–153
treatment complications, 183–185
trade names of drugs, 195–196
training, 4–5
transcription errors, 188–189
prescription writing, 32
transcultural issues, 61–62
treatment refusal, court cases, 37, 38
trust and sharing values, 8
type 1 diabetes, 102
insulin therapy, 104–105
monitoring of, 105
type 2 diabetes, 102–103
management of, 103–104
monitoring of
unit costs of drugs, 162–165
calculating, 147–148
amount, 152
mass, 149–151
practice calculations, 152–153
prefixes, 148
volume, 148–149
utilitarian ethics, 44–45

Cambridge University Press
Edited by Molly Courtenay and Matt Griffiths
Index
More information
<table>
<thead>
<tr>
<th>Vaccination</th>
<th>Indications and contraindications, 139–140</th>
<th>Weekly dosing schedules, problems with, 193–195</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse media publicity, 62</td>
<td>Storage, distribution and disposal, 139</td>
<td>Weight, units of, 149–151</td>
</tr>
<tr>
<td>Consent for, 139</td>
<td>Veracity, 48</td>
<td>Yellow Book, 141</td>
</tr>
<tr>
<td>Immunisation schedule, 140–141</td>
<td>Volume of distribution (Vd) of a drug, 71–72</td>
<td>Yellow Card scheme, 36, 83, 120</td>
</tr>
<tr>
<td>Policy on, 138–139</td>
<td>Volume, units of, 148–149</td>
<td></td>
</tr>
<tr>
<td>Procedures for, 140</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccines</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>